ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Indonesia receives first COVID vaccine from China's Sinovac

Inoculation plans proceed as regulators evaluate efficacy

A mural promotes awareness of the coronavirus outbreak in Jakarta.   © Reuters

JAKARTA (Reuters) -- Indonesia received its first shipment of coronavirus vaccine from China on Sunday, President Joko Widodo said, as the government prepares a mass inoculation programme.

Jokowi, as the president is widely known, said in an online briefing that the Southeast Asian country received 1.2 million doses from China's Sinovac Biotech Ltd., a vaccine Indonesia has been testing since August.

He added that the government plans to receive another 1.8 million doses in early January.

Late-stage trials of the Sinovac vaccine are also under way in Brazil and Turkey, with interim results on efficiency from Brazil expected by mid-December.

Indonesia is also expected this month to receive shipments of raw materials to produce 15 million doses and materials for 30 million doses next month, the president said.

The vaccine still needs to be evaluated by the country's food and drug agency (BPOM) while his administration continues to prepare for distributing the vaccine across the vast archipelago of 270 million people, Jokowi said.

"We have been preparing for months through simulations in several provinces and I am sure that once it is decided that we can begin the vaccination, everything will be ready," he said.

Indonesia's daily number of coronavirus infections have accelerated in recent weeks, with total confirmed cases reaching 575,796 on Sunday with 17,740 deaths, the highest in Southeast Asia.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more